Anixa Biosciences Advances CAR-T and Vaccine Programs as Phase 1 Trials Show Promise — Anixa Biosciences, Inc.

Event summary

Anixa Biosciences to present at H.C. Wainwright conference on September 11, 2026, detailing progress in ovarian cancer CAR-T therapy and breast cancer vaccine.
Ovarian cancer CAR-T therapy lira-cel advances to highest dose level in fifth cohort with lymphodepletion; four patients surpass one year of survival, longest at 28 months.
Breast cancer vaccine Phase 1 trial meets all primary endpoints with 74% of participants showing immune responses; Phase 2 preparations underway.
Collaborations with Moffitt Cancer Center and Cleveland Clinic highlighted in presentation.

The big picture

Anixa Biosciences is making significant strides in its clinical programs, particularly in the areas of CAR-T therapy for ovarian cancer and vaccine development for breast cancer. The company's strategic partnerships with leading cancer research institutions like Moffitt Cancer Center and Cleveland Clinic position it well to navigate the complex landscape of oncology drug development. The upcoming presentation at the H.C. Wainwright conference will provide further insights into the company's progress and future directions in the biotech sector.

What we're watching

Clinical Progress: Whether Anixa can sustain the promising results from its Phase 1 trials in subsequent stages of development.
Regulatory Pathway: The pace at which Anixa advances its breast cancer vaccine and ovarian cancer CAR-T therapy through Phase 2 trials and potential regulatory approvals.
Strategic Partnerships: How Anixa's collaborations with Moffitt Cancer Center and Cleveland Clinic will influence the commercialization of its therapeutic portfolio.